B2i Digital

Applied Energetics (OTCQB: AERG) recently participated in the Force Webinar, hosted by Force Family Office, where CEO Chris Donaghey shared insights into the company’s strategic direction, advanced laser technology, and ongoing defense collaborations. The event showcased Applied Energetics’ commitment to ultrashort pulse laser (USPL) technology for national security and commercial applications. Applied Energetics, Inc. is a B2i Digital Featured Company. View the company’s profile at https://lnkd.in/eVEkcBCH FORCE Family Office is the largest network of family offices in the United States, representing more than 200,000 members worldwide and providing a platform for knowledge sharing, co-investment, and philanthropy. Among the topics covered were: · The potential of ultrashort pulse laser technology to address modern defense challenges. · Recent advancements in USPL system integration and testing. · Collaborations with U.S. military branches, including the Army, Navy, and Marine Corps. · The strategic significance of the Battle Lab facility in Tucson, Arizona. · The company’s vision for expanding applications of USPL across defense and commercial sectors. Chris Donaghey commented, “We believe we are the first company that is developing a capability that is positioned to be the catalyst to put the bend in the adoption curve for directed energy. So how are we going to do that? By focusing on ultrashort pulse lasers. The objective here is to defeat sensors of all kinds across a broad range of enemy threat platforms. Again, we’re starting out with a focus on small drones, but this applies, as you’ll see, across a much broader range of threats.” View the entire Force Webinar at https://lnkd.in/edKeTDhY Backed by more than $50 million in public and private investment and protected by 26 issued patents and 8 pending applications, Applied Energetics is the only U.S. public company focused exclusively on ultrashort pulse laser (USPL) technology for national security. With a growing addressable market, projected to reach $32.1 billion for directed energy weapons and $7.1 billion for counter-UAS by 2030, the company is positioned at the forefront of a rapidly evolving industry. The leadership team, including Chris Donaghey (CEO), Bradford T. Adamczyk (Executive Chairman), Dr. Stephen McCahon (Co-Founder & Chief Scientist), Gregory Quarles (CEO Emeritus), and Mary O. (General Counsel & CLO), operates from a state-of-the-art, 26,800 sq. ft. facility at the University of Arizona Tech Park. Recent milestones include successfully demonstrating a terawatt-class USPL platform and mission-relevant contracts with the U.S. Marine Corps, Army, and Navy. Learn more about Applied Energetics at https://lnkd.in/eP5rbxAG. For investor inquiries, contact Kevin McGrath at kevin@cameronassoc.com or (646) 418-7002. #AppliedEnergetics #DirectedEnergy #ForceWebinar #B2iDigital

OS Therapies (NYSE-A: OSTX) announced that the company will hold an Analyst Day at the New York Stock Exchange on April 7, 2025, at 10:00 AM ET. Hosting the event at the iconic NYSE reflects the company’s growing presence and continued momentum as it prepares to share important updates with investors and industry leaders. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB The event will spotlight the OST-HER2 program for recurrent, fully resected lung metastatic osteosarcoma, which OS Therapies is positioning for Accelerated Approval in late 2025. Attendees will also hear about advancements in the OST-HER2 canine osteosarcoma program, new initiatives targeting HER2+ breast cancer and other solid tumors, and updates on the tunable ADC (tADC) platform, part of the company’s broader innovation strategy. The pipeline of assets recently acquired from Ayala Pharmaceuticals will also be featured. See the full news release at https://lnkd.in/evMX7AnZ For additional information about the event, please see  https://lnkd.in/e5QgCVdN OS Therapies recently gained new research coverage from Lake Street Capital Markets, highlighting growing interest in the company’s strategic progress. The initiation report by Chad Messer, Ph.D., outlines the company’s investment thesis, Listeria Platform, management profile, valuation, and near-term milestones. OS Therapies is a clinical-stage oncology company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. The company’s lead product candidate, OST-HER2, leverages Listeria-based immunotherapy to stimulate a robust immune response against HER2-expressing cancer cells. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates. For investor-related questions, please visit OS Therapies’ Investor Relations page or email irpr@ostherapies.com. DISCLOSURE: The management of B2i Digital owns 2,000 shares of unrestricted OSTX stock purchased in the open market as of April 2, 2025. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://lnkd.in/epFNRZQB.

OS Therapies (NYSE-A: OSTX) announced full-year 2024 financial results, highlighting significant progress and continued strategic advancements. The company remains focused on achieving regulatory approval for OST-HER2 in osteosarcoma and advancing its pipeline of innovative cancer therapies. OS Therapies is a B2i Digital Featured Company. See their profile and learn more about OS Therapies at https://lnkd.in/epFNRZQB Highlights from the announcement include: · Completed the treatment phase of the Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma. · Positive Phase 2b data showed statistically significant benefit in the 12-month event-free survival (EFS) primary endpoint. · The rolling BLA submission for OST-HER2 is expected to begin in mid-2025, targeting regulatory approval by year-end. ·  A recently completed $6 million private placement is expected to provide a sufficient cash buffer to support operations into 2026. ·  Planned presentation of full clinical data from the OST-HER2 Phase 2b trial at the MIB Factor Conference in June 2025. Commenting on the results, Paul Romness, MPH, Chairman & CEO of OS Therapies, stated: “2024 was a transformative year for OS Therapies as we completed our initial public offering and finalized the treatment phase of our Phase 2b clinical trial in the prevention of recurrence in fully resected, lung metastatic osteosarcoma. The company remains primarily focused on gaining a Biologics Licensing Authorization (BLA) for OST-HER2 in osteosarcoma that would trigger the issuance of a Priority Review Voucher (PRV) that the company expect to then divest in order to capitalize with non-dilutive capital to allow the company to fully exploit the OST-HER2 immunotherapeutic candidate and the rest of the Lm platform.” See the full news release here: https://lnkd.in/efJQkWdC In addition, OS Therapies is scheduled to present at NYSE Analyst Day on April 7, 2025, at 10:00 AM ET, featuring a keynote with CEO, Paul Romness. For more information, please see https://lnkd.in/e5QgCVdN OS Therapies is a clinical-stage oncology company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. The company’s lead product candidate, OST-HER2, leverages Listeria-based immunotherapy to stimulate a robust immune response against HER2-expressing cancer cells. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers.

Intelligent Bio Solutions (NASDAQ: INBS) has integrated Arabic as the second international language into its Intelligent Fingerprinting Drug Screening System, enhancing accessibility for organizations across the Middle East. Part of the Company’s broader multilingual upgrade, this integration supports its global expansion strategy and helps serve Arabic-speaking users in safety-critical industries, law enforcement, and drug rehabilitation. Intelligent Bio Solutions is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/gCF9hkFm. Harry Simeonidis, President & CEO of INBS, commented, “Expanding language support is a crucial step in ensuring our expanded global reach and accessibility of our solution to organizations worldwide. Arabic was a logical choice for the second language integrated into our system, given its wide use across the globe. Adding Arabic to our system strengthens our capabilities and presence in the Middle East and will provide more businesses with an intuitive and reliable drug testing solution.” See the INBS full announcement at https://lnkd.in/ePtAZ8yh Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is committed to revolutionizing drug screening with its hygienic, rapid, and cost-effective fingerprint sweat-based solution. The Company’s non-invasive, patented technology enables on-site drug screening in just minutes, offering many advantages over traditional testing methods. INBS serves a broad range of industries, including workplace safety, law enforcement, drug treatment, and forensics, with a growing global footprint of 400+ accounts across 19 countries. The Company’s talented global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications. #IntelligentBioSolutions #INBS #B2iDigital #MiddleEastExpansion #NonInvasiveTesting

Unicycive Therapeutics (Nasdaq: UNCY) announced that the company will attend the 24th Annual Needham Virtual Healthcare Conference. Dr. Shalabh Gupta, CEO, will present on April 7, 2025, at 2:15 PM ET. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f. The annual Needham conference is considered one of the most influential events in the healthcare industry, attracting leading companies from biopharma, medtech, diagnostics, and digital health sectors. This year’s event will feature presentations, fireside chats, one-on-one meetings, and panel discussions. Unicycive’s audience will include institutional, private equity, and venture capital investors who can engage directly with the company and share its vision for advancing kidney disease treatments. See the full news release here: https://lnkd.in/e9Sk4XiS Unicycive continues to attract growing interest from sell-side research firms, including Noble Capital Markets, one of the seven firms providing coverage. Following Unicycive’s earnings release yesterday, Noble updated Unicycive’s progress and expectations for the upcoming Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. Interested investors may contact Noble directly for access to the firm’s research.Unicycive Therapeutics is a clinical-stage biotechnology company focused on innovative therapies for kidney diseases. Its lead asset, OLC, is a next-generation phosphate binder in development for hyperphosphatemia, using proprietary nanoparticle technology to reduce pill burden. The company is also advancing UNI-494, a novel treatment for acute kidney injury. Led by CEO Dr. Shalabh Gupta, MD Gupta and a highly experienced executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment. Please visit Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/) to learn more and follow Unicycive’s journey as the company advances innovative treatments for kidney disease. #Unicycive #UNCY #B2iDigital #KidneyDisease #Hyperphosphatemia DISCLOSURE: Management of B2i Digital owns a total of 80,670 shares of unrestricted UNCY stock as of April 1, 2025. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://lnkd.in/eg9U-h4f.

#Unicycive announced their full year 2024 financials today and provided a corporate update. You can read more about our progress here: https://lnkd.in/gC5q4m8X

🎶 Why the Music Industry Keeps Rocking—Even in Tough Times 🎶 The music industry, like a chart-topping hit—strives to persevere, evolve, and always be in demand. No matter the economy, people have kept streaming, singing, and spending. Remember 2008? While industries crumbled, music went digital. In 2020? No live shows? No problem—livestreams took center stage. And today? Goldman Sachs predicts music industry revenues will hit $163B+ by 2030*! 🎧 So how do you get a backstage pass to this resilient industry? MUSQ Global Music Industry Index ETF (NYSE: MUSQ) lets you invest in streaming, licensing, live entertainment & more. Don't just listen—invest! 🎶 Ready to see how the music industry keeps rocking no matter what? Hit play and dive in! 🎧👉https://lnkd.in/e5fHFgsP * Source: Goldman Sachs, Music in the Air Report, May 1, 2024

NDASA 2025, the National Drug and Alcohol Screening Association (NDASA) Annual Conference & Trade Show, will be in Jacksonville, Florida, April 1-4, 2025, and Intelligent Bio Solutions (Nasdaq: INBS) is proud to be a Gold Sponsor. Additionally, INBS will present at the Symposium on April 1. Intelligent Bio Solutions is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/gCF9hkFm. NDASA’s Conference and Trade Show is widely recognized as the premier event for the drug and alcohol testing industry. This year, attendees can look forward to an extra day of education and innovation, featuring expert-led professional training sessions, nationally respected speakers, and extensive networking opportunities. Building on the record-breaking success of last year’s sold-out event in Hershey, Pennsylvania, NDASA 2025 promises to deliver even greater insights and opportunities for industry professionals. A limited number of seats are still open for those who want to attend: Registration link https://lnkd.in/esmm8W5Q Daniel Brown, PhD, Head of Clinical Affairs at IBS, noted, “The NDASA conference brings together key voices in workplace drug testing. We’re proud to support its mission and contribute to the conversation around practical, respectful testing alternatives that address today’s workplace safety challenges.” See the INBS full announcement at https://lnkd.in/eWY4ZSAF. Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is committed to revolutionizing drug screening with its hygienic, rapid, and cost-effective fingerprint sweat-based solution. The Company’s non-invasive, patented technology enables on-site drug screening in just minutes, offering many advantages over traditional testing methods. INBS serves a broad range of industries, including workplace safety, law enforcement, drug treatment, and forensics, with a growing global footprint of 400+ accounts across 19 countries. The Company’s talented global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications. #IntelligentBioSolutions #INBS #B2iDigital #NDASA2025 #WorkplaceSafety

Newton Golf Company (Nasdaq: NWTG) announced fourth quarter and full-year 2024 financial results, highlighting significant progress driven by strategic product launches, international expansion, and continued operational momentum. The company reported record revenue growth and substantial margin expansion, reinforcing its position as a leader in premium golf equipment innovation. Newton Golf is a B2i Digital Featured Company. View their comprehensive B2i Digital Featured Company Profile at https://lnkd.in/eCG_9VA6. Among the highlights were: - Fourth quarter revenue of $1.073 million, an 817% increase from $117,000 in Q4 2023. - Fourth quarter gross margin of 73%, up from 36% in Q4 2023. - Full-year revenue of $3.445 million, representing an 887% increase from $349,000 in fiscal 2023. - Full-year gross margin improved to 67%, compared to 35% in fiscal 2023. - Expanded product portfolio with new offerings, including the Newton Fairway Motion Shafts, five new Newton Gravity putter models, and the new Fast Motion shaft line. - Broadened global presence with distribution in 50 of Japan’s largest golf retail locations. - Increased tour adoption, including 30+ players using the Newton Motion Shaft on the PGA TOUR Champions in 2024, with continued traction on the PGA Tour and LPGA Tour. Commenting on the news, Chairman and CEO Greg Campbell noted, “2024 was a transformative year for Newton Golf, as we successfully executed our strategic vision and delivered exceptional financial and operational performance. Our tenfold revenue growth, substantial margin expansion, and increasing tour adoption demonstrate the effectiveness of our innovation and market strategy. With expanding tour presence, including players on the PGA Tour and LPGA Tour, and the launch of our new Fast Motion shaft line, we continue to drive industry-leading performance and brand recognition. With a strong foundation in place, we are focused on scaling operations, expanding global distribution, and driving sustained growth in 2025 and beyond.” See the Company’s full news release here: https://lnkd.in/eYDK7bPN. Newton Golf is a technology-forward golf brand recognized for its ultra-light carbon fiber shafts, ULBP putter technology, and weight-forward CG design. The Company is focused on producing premium golf equipment in the U.S. while expanding into new product lines and international markets. Led by Executive Chairman Greg Campbell, Newton Golf’s leadership team brings deep industry expertise, including Chief Technology Officer Akinobu Yorihiro . For investor-related inquiries, please contact Investor Relations at ir@newtongolfoco.com. #NewtonGolf #GolfInnovation #FinancialResults #B2iDigital #Q4Results

Unicycive Therapeutics (Nasdaq: UNCY) reported substantial progress in 2024, announcing full-year financial results and providing a business update that highlighted advancements in its New Drug Application (NDA) for oxylanthanum carbonate (OLC), which is currently under FDA review. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025. Unicycive is preparing for the potential commercial launch of OLC in late 2025. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eg9U-h4f Highlights from the announcement include: - The acceptance of the NDA for OLC for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. - Ongoing commercial planning and preparation for the anticipated launch of OLC. - Significant publication of data, including in the peer-reviewed journals Clinical Therapeutics, Clinical and Translational Science, and Journal of Nephrological Science. These publications highlight OLC’s safety, efficacy in controlling serum phosphate levels, and bioequivalence to approved lanthanum carbonate chewable tablets. - Successful completion of the Phase 1 study of UNI-494, demonstrating favorable tolerability, fast absorption, and rapid metabolization. Dr. Shalabh Gupta, MD, CEO of Unicycive, commented: “2025 is positioned to be a transformational year for Unicycive, with the near-term potential for FDA approval and commercial launch of oxylanthanum carbonate (OLC). For approximately 75% of people in the U.S. with chronic kidney disease (CKD) on dialysis, hyperphosphatemia remains uncontrolled because of challenges with currently available phosphate binders, potentially increasing their risk of hospitalization and mortality. If approved, we believe OLC is positioned to be an important new option for these patients, distinguished by its high potency and a low pill burden. We continue to actively prepare to launch OLC, including educating key stakeholders on existing OLC data and preparing our commercial infrastructure to rapidly make OLC available to patients upon approval.” For full details, read the announcement at https://lnkd.in/ejuunsj5 Unicycive Therapeutics is a clinical-stage biotechnology company focused on innovative therapies for kidney diseases. Its lead asset, OLC, is a next-generation phosphate binder in development for hyperphosphatemia, utilizing proprietary nanoparticle technology to reduce pill burden. The company is also advancing UNI-494, a novel treatment for acute kidney injury. Led by CEO Dr. Shalabh Gupta and a highly experienced executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment.